ALLOGENE THERAPEUTICS

Allogene Therapeutics Unveils Novel Approach to Generate Engineered AlloCAR T™ Cells to Control Immune Rejection at the Annual Meeting of the Society for Immunotherapy of Cancer

10 11 2022 08:00:02 提供 Nasdaq GlobeNewswire

Allogene Therapeutics To Host Research & Development Showcase and Participate in Five Upcoming Investor Conferences

09 11 2022 07:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Announces Poster Presentation of Its Phase 1 UNIVERSAL Trial in Multiple Myeloma at the 64th Annual Meeting of the American Society of Hematology

03 11 2022 08:04:36 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Reports Third Quarter 2022 Financial Results and Announces Investor R&D Showcase

02 11 2022 15:02:00 提供 Nasdaq GlobeNewswire

Allogene Overland Biopharm Completes Buildout of cGMP Manufacturing Facility in Shanghai to Support the Development of AlloCAR T™ Products in Asia

31 10 2022 07:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics to Report Third Quarter 2022 Financial Results on November 2, 2022

26 10 2022 07:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Launches CAR T Together™, a First-of-its-Kind Initiative with Leading Oncologists Nationwide, Focused on Accelerating Development and Clinical Trial Recruitment for “Off-The-Shelf” Allogeneic Cell Therapy Investigational Products

11 10 2022 07:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Initiates Industry’s First Allogeneic CAR T Phase 2 Trial

06 10 2022 15:15:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in the Jefferies Cell and Genetic Medicine Summit

23 9 2022 07:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Reports Second Quarter 2022 Financial Results

09 8 2022 15:02:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences

03 8 2022 07:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022

27 7 2022 07:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Appoints Scientific Pioneer Stephen Mayo to its Board of Directors

12 7 2022 07:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma

08 6 2022 07:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Improved Anti-Tumor Activity of Donor-Derived Allogeneic CAR T Cells at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

19 5 2022 07:30:01 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Named 2022 Bay Area “Best Place to Work” by San Francisco Business Times and Silicon Valley Business Journal

09 5 2022 07:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Reports First Quarter 2022 Financial Results

04 5 2022 15:02:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Appoints Susan Lundeen as Chief People Officer

28 4 2022 07:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics to Report First Quarter 2022 Financial Results on May 4, 2022

27 4 2022 07:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First TurboCAR™ T Cell Product Candidate, for the Treatment of Multiple Myeloma

27 4 2022 07:00:01 提供 Nasdaq GlobeNewswire